adenovector-based foot-and-mouth disease vaccine

The adenovector-based foot-and-mouth disease (FMD) vaccine is a recombinant, replication-deficient viral vector vaccine designed to protect livestock, such as cattle and swine, against the foot-and-mouth disease virus (FMDV). Developed through a collaboration between the USDA Agricultural Research Service, the Department of Homeland Security, and industry partners including Zoetis and GenVec (now Precigen), the vaccine utilizes a human adenovirus type 5 (Ad5) platform. This vector delivers the genetic sequences for the FMDV capsid precursor protein (P1-2A) and the 3C protease into host cells, where they are expressed and assemble into non-infectious virus-like particles (VLPs) that mimic the structure of the native virus. A significant advantage of this technology is its compatibility with Differentiating Infected from Vaccinated Animals (DIVA) diagnostic strategies, as the vaccine lacks the non-structural proteins (e.g., 3ABC) produced during natural infection. Furthermore, because the vaccine does not contain live FMDV, it can be safely manufactured in the United States without the high-containment facilities (BSL-3Ag) required for traditional inactivated FMD vaccines.

Brand names

FMD-Vectored Vaccine

Other names

Ad5-FMDV vaccineAd-5-FMDV vaccineAd 5-FMDV vaccineAdenovirus-vectored FMD vaccineRecombinant adenovirus-vectored FMD vaccine